383 related articles for article (PubMed ID: 15572386)
1. Factors associated with increased plasma homocysteine in patients using an amino acid peritoneal dialysis fluid.
Yang SY; Huang JW; Shih KY; Hsu SP; Chu PL; Chu TS; Wu KD
Nephrol Dial Transplant; 2005 Jan; 20(1):161-6. PubMed ID: 15572386
[TBL] [Abstract][Full Text] [Related]
2. Solutes transport characteristics in peritoneal dialysis: variations in glucose and insulin serum levels.
da Silva DR; Figueiredo AE; Antonello IC; Poli de Figueiredo CE; d'Avila DO
Ren Fail; 2008; 30(2):175-9. PubMed ID: 18300117
[TBL] [Abstract][Full Text] [Related]
3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
4. Amino-acid-based dialysis solution changes leptinemia and leptin peritoneal clearance.
Grzegorzewska AE; Wiecek A; Mariak I; Kokot F
Adv Perit Dial; 2000; 16():7-14. PubMed ID: 11045252
[TBL] [Abstract][Full Text] [Related]
5. [Hyperhomocysteinemia in CAPD patients: peritoneal transport of total homocysteine at peritoneal equilibration test and daily elimination of total homocysteine].
Hirose S; Kono R; Mitarai T; Isoda K; Kim S; Shimoyama H
Nihon Jinzo Gakkai Shi; 1999 Dec; 41(8):778-86. PubMed ID: 10655726
[TBL] [Abstract][Full Text] [Related]
6. Correlates of habitual physical activity in chronic haemodialysis patients.
Zamojska S; Szklarek M; Niewodniczy M; Nowicki M
Nephrol Dial Transplant; 2006 May; 21(5):1323-7. PubMed ID: 16421165
[TBL] [Abstract][Full Text] [Related]
7. What is the meaning of homocysteine in patients on dialysis?
Silva de Almeida CC; Guerra DC; Vannucchi MT; Geleilete TJ; Vannucchi H; Chiarello PG
J Ren Nutr; 2011 Sep; 21(5):394-400. PubMed ID: 21439851
[TBL] [Abstract][Full Text] [Related]
8. Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients.
Aguilera A; Bajo MA; Rebollo F; Díez JJ; Díaz C; Paiva A; Codoceo R; Selgas R
Adv Perit Dial; 2002; 18():212-7. PubMed ID: 12402621
[TBL] [Abstract][Full Text] [Related]
9. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients--Italian initiative on uremic hyperhomocysteinemia (IIUH).
Perna AF; Ingrosso D; Molino D; Galletti P; Montini G; Zacchello G; Bellantuono R; Caringella A; Fede C; Chimenz R; De Santo NG
J Nephrol; 2003; 16(4):516-21. PubMed ID: 14696753
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for dietary protein intake in CAPD patients.
Piraino B
Adv Perit Dial; 1996; 12():275-9. PubMed ID: 8865918
[TBL] [Abstract][Full Text] [Related]
12. Is malnutrition an independent predictor of mortality in peritoneal dialysis patients?
Chung SH; Lindholm B; Lee HB
Nephrol Dial Transplant; 2003 Oct; 18(10):2134-40. PubMed ID: 13679492
[TBL] [Abstract][Full Text] [Related]
13. Relationships between homocysteine and related amino acids in chronic hemodialysis patients.
McDonald SP; Whiting MJ; Tallis GA; Barbara JA
Clin Nephrol; 2001 Jun; 55(6):465-70. PubMed ID: 11434358
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with body-fat changes in prevalent peritoneal dialysis patients.
Vasselai P; Kamimura MA; Bazanelli AP; Pupim LB; Avesani CM; da Mota Ribeiro FS; Manfredi SR; Draibe SA; Cuppari L
J Ren Nutr; 2008 Jul; 18(4):363-9. PubMed ID: 18558301
[TBL] [Abstract][Full Text] [Related]
15. Adequacy and nutrition in pediatric peritoneal dialysis.
Cano FJ; Marín VS; Azocar MA; Delucchi MA; Rodriguez EE; Diaz ED; Villegas RC
Adv Perit Dial; 2003; 19():273-8. PubMed ID: 14763078
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation.
Rodrigues AS; Almeida M; Fonseca I; Martins M; Carvalho MJ; Silva F; Correia C; Santos MJ; Cabrita A
Nephrol Dial Transplant; 2006 Mar; 21(3):763-9. PubMed ID: 16332703
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress in chronic renal failure patients treated by peritoneal dialysis.
Al-Hashimi AF; Mohammed FH; Al-Khazragi AS
Saudi Med J; 2004 Sep; 25(9):1186-92. PubMed ID: 15448763
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease.
Vrentzos GE; Papadakis JA; Vardakis KE; Maliaraki N; Stilianou K; Arvanitis A; Sratigis S; Alivanis P; Margioris AN; Ganotakis ES
J Nephrol; 2003; 16(4):535-9. PubMed ID: 14696755
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of peritoneal transport properties at onset of peritoneal dialysis and longitudinal follow-up.
Clerbaux G; Francart J; Wallemacq P; Robert A; Goffin E
Nephrol Dial Transplant; 2006 Apr; 21(4):1032-9. PubMed ID: 16364990
[TBL] [Abstract][Full Text] [Related]
20. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
